| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA277069
Max Phase: Preclinical
Molecular Formula: C15H23N3O10
Molecular Weight: 405.36
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: NC[C@H]1O[C@@H](O[C@@H](CO)[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)[C@H](O)[C@@H]1O
Standard InChI: InChI=1S/C15H23N3O10/c16-3-5-8(21)11(24)14(26-5)27-6(4-19)12-9(22)10(23)13(28-12)18-2-1-7(20)17-15(18)25/h1-2,5-6,8-14,19,21-24H,3-4,16H2,(H,17,20,25)/t5-,6+,8-,9+,10-,11-,12-,13-,14+/m1/s1
Standard InChI Key: CSZXHEFWJRKHDV-SJKWGPLLSA-N
Associated Targets(non-human)
Phospho-N-acetylmuramoyl-pentapeptide-transferase 27 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 405.36 | Molecular Weight (Monoisotopic): 405.1383 | AlogP: -5.06 | #Rotatable Bonds: 6 |
| Polar Surface Area: 209.72 | Molecular Species: BASE | HBA: 12 | HBD: 7 |
| #RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 9.70 | CX Basic pKa: 8.75 | CX LogP: -4.58 | CX LogD: -5.70 |
| Aromatic Rings: 1 | Heavy Atoms: 28 | QED Weighted: 0.24 | Np Likeness Score: 1.53 |
References
| 1. Dini C, Didier-Laurent S, Drochon N, Feteanu S, Guillot JC, Monti F, Uridat E, Zhang J, Aszodi J.. (2002) Synthesis of sub-micromolar inhibitors of MraY by exploring the region originally occupied by the diazepanone ring in the liposidomycin structure., 12 (8): [PMID:11934590] [10.1016/s0960-894x(02)00109-9] |
| 2. Dini C, Collette P, Drochon N, Guillot JC, Lemoine G, Mauvais P, Aszodi J.. (2000) Synthesis of the nucleoside moiety of liposidomycins: elucidation of the pharmacophore of this family of MraY inhibitors., 10 (16): [PMID:10969981] [10.1016/s0960-894x(00)00349-8] |
| 3. Dini C, Drochon N, Guillot JC, Mauvais P, Walter P, Aszodi J.. (2001) Synthesis of analogues of the O-beta-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 2: role of the hydroxyl groups upon the inhibition of MraY., 11 (4): [PMID:11229764] [10.1016/s0960-894x(00)00714-9] |
| 4. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G.. (2019) Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY., 171 [PMID:30933853] [10.1016/j.ejmech.2019.01.071] |
| 5. Serpi M, Ferrari V, Pertusati F.. (2016) Nucleoside Derived Antibiotics to Fight Microbial Drug Resistance: New Utilities for an Established Class of Drugs?, 59 (23): [PMID:27607900] [10.1021/acs.jmedchem.6b00325] |
Source
Source(1):